🧬 BioMed Pulse · 2026-11-16 02:01 UTC
BIOMED PULSE
Monday, November 16, 2026 | Your daily briefing on longevity, viruses, and new cures
⚡ TL;DR
The Bundibugyo virus (Ebola) outbreak in the Democratic Republic of the Congo has now spread to Kenya and Nigeria and continues to intensify, making it the largest Ebola outbreak ever recorded — a defining global health emergency. Mood: urgent on outbreak containment; cautiously constructive on longevity science.
🦠 OUTBREAKS & VIRUSES
BUNDIBUGYO VIRUS DISEASE (EBOLA) — DRC, KENYA, NIGERIA
- As of the November 6 WHO Disease Outbreak News update, sustained high-level transmission of Bundibugyo virus disease (BVD) continues across the DRC, with geographic expansion ongoing since the June 13 first WHO DON report. [1] [2]
- The outbreak has now crossed into Kenya (imported case confirmed October 5, traveler from DRC via Uganda) and Nigeria, making this a multi-country event per the October 23 and November 6 WHO DON reports. [3] [4] [2]
- As of the July 17 WHO update, cumulative confirmed cases had already reached 2,124 with 828 deaths; the August and September updates documented further spread across six provinces and 60-plus health zones in DRC. [5] [6] [7]
- The outbreak was declared the largest Ebola outbreak ever reported in DRC and was described as expanding faster than any previous Ebola outbreak in the August 14 WHO DON. [8]
- CDC mobilized an international Ebola response as of May 17, 2026, and enhanced airport screening was deployed at Washington-Dulles and Atlanta airports in late May. [9] [10]
SHAMONDA VIRUS — FRANCE (FIRST HUMAN CASE)
- On October 20, 2026, France notified WHO of the world's first documented human infection with Shamonda virus (SHAV), a novel pathogen, in an immunocompromised older man from eastern France with no recent travel history.
- The patient developed severe neurological symptoms; the case was posted as a WHO Disease Outbreak News on November 2, 2026, and is under active investigation.
MERS-COV — QATAR
- Qatar notified WHO on October 29, 2026, of two laboratory-confirmed MERS-CoV cases, confirmed August 5 and 25, 2026 — the first MERS cases Qatar has reported per the November 13, 2026 WHO DON.
- Saudi Arabia separately reported eight laboratory-confirmed MERS-CoV cases including one death between January 1 and October 5, 2026, across six locations including Riyadh and Tabuk.
YELLOW FEVER — WHO AFRICAN REGION
- Between January 1 and October 12, 2026, nine countries in the WHO African Region recorded 67 confirmed yellow fever cases including 18 deaths; affected countries include Burkina Faso, Cameroon, and the Central African Republic, per the November 6 WHO DON.
- Separately, six countries in the Americas reported 79 human infections from January 1 to May 26, 2026, reflecting ongoing transmission that carried over from a 2025 surge.
PNEUMONIA OF UNDETERMINED ETIOLOGY — RUSSIA
- On October 2, 2026, WHO was notified of the death of an employee of the Irkutsk Antiplague Research Institute of Siberia from severe pneumonia; cause remains undetermined per the October 10 WHO DON.
NIPAH VIRUS — INDIA (JUNE)
- One laboratory-confirmed Nipah virus case was reported in Kozhikode district, Kerala, India on June 11, 2026; the adult male presented with neurological symptoms and was hospitalized June 10.
ANDES HANTAVIRUS — CRUISE SHIP (ONGOING MONITORING)
- The Andes hantavirus (ANDV) outbreak linked to the M/V Hondius cruise ship, first notified to WHO May 2, 2026, was the subject of a fifth WHO Disease Outbreak News posting dated July 2, 2026, with ongoing international monitoring of affected travelers.
🧬 LONGEVITY & AGING
GDF11 AND MUSCLE AGING
- A Europe PMC study (Genes and Disease, published February 2026) found that GDF11, a blood factor that declines with age, restores skeletal muscle satellite cell function via the MYC pathway to ameliorate sarcopenia — age-related muscle loss that affects mobility and independence in older adults.
MTORC1 SILENCING FOR DISC DEGENERATION
- Researchers published in Bioactive Materials (October 2026) that cationized gelatin nanospheres delivering RNA interference targeting mTORC1 protected against intervertebral disc degeneration in a controlled-release model, pointing toward a potential gene-silencing approach to a major cause of chronic back pain in aging populations.
PHYSICAL ACTIVITY AS AN AGING CLOCK
- A Lancet Healthy Longevity commentary (Suetta, September 2026) argues that physical function and muscle health are more clinically meaningful "aging clocks" than chronological age, urging their use as standard clinical endpoints in geroscience research.
- Multiple Lancet Healthy Longevity papers (King, Valenzuela, Sánchez-Sánchez, and colleagues, 2026-2027) converge on a consensus that multilevel physical activity promotion is a top public health priority for healthy aging in both high-income and low-to-middle-income countries.
CLINICALAGE — EHR-BASED AGING TRAJECTORY MODEL
- A Lancet Digital Health model development study (Lian and colleagues) introduced ClinicalAge, a framework that models individualized aging trajectories from longitudinal electronic health records in the UK, validated against mortality and functional outcomes.
- A companion commentary in Lancet Digital Health (Zhu and Hu) describes a novel aging biomarker capable of capturing aging trajectories from EHR data, potentially enabling earlier clinical intervention.
AI FACE-BASED BIOLOGICAL AGE ESTIMATION
- A Lancet Digital Health model development and validation study (Haugg, Lee, Gladyshev, Aerts, Mak and colleagues) developed FAHR-Face, a foundation AI model that estimates biological age and health status from face photographs, validated against clinical outcomes.
ANIMAL PROTEIN, COGNITION, AND DEMENTIA DISPARITIES
- A global ecological analysis in Future Science OA (November 2026) found associations between animal protein supply, cognitive aging trajectories, and female-male dementia disparities across countries, raising questions about dietary protein as a modifiable factor in brain aging.
💊 NEW CURES & APPROVALS
OXDERYS (DOXORUBICIN HYDROCHLORIDE) — AVYXA HOLDINGS
- Avyxa Holdings received an original FDA approval (NDA221093) for Oxderys, a doxorubicin hydrochloride formulation; doxorubicin is a cytotoxic anthracycline used in multiple cancers.
TOFACITINIB CITRATE GENERICS — APOTEX AND DEXCEL
- Apotex (ANDA220458) and Dexcel (ANDA218668) each received original FDA approvals for generic tofacitinib citrate, a JAK inhibitor used in rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, expanding affordable access.
POHERDY (PERTUZUMAB-DPZB) — SHANGHAI HENLIUS BIOTECH
- Shanghai Henlius Biotech received a supplemental FDA approval (BLA761450) for Poherdy, a pertuzumab biosimilar targeting HER2-positive breast cancer.
GAVRETO (PRALSETINIB) — RIGEL PHARMACEUTICALS
- Rigel Pharmaceuticals received a supplemental FDA approval (NDA213721) for Gavreto (pralsetinib), a RET kinase inhibitor for RET-altered non-small cell lung cancer and thyroid cancers.
ZOKINVY (LONAFARNIB) — SENTYNL THERAPEUTICS
- Sentynl Therapeutics received a supplemental FDA approval (NDA213969) for Zokinvy (lonafarnib), a farnesyltransferase inhibitor approved for Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies, rare premature aging diseases.
DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE — MICRO LABS
- Micro Labs received a supplemental FDA approval (ANDA211466) for a generic dapagliflozin-metformin combination, an SGLT2 inhibitor plus biguanide regimen used in type 2 diabetes management.
BAYER NDA221291
- Bayer Healthcare received an original FDA approval (NDA221291); full active ingredient details were not specified in the source data.
🧪 CLINICAL TRIALS
ALL-ORAL TRIPLE COMBINATION FOR IDH1-MUTANT AML — NEW TRIAL
- A prospective multicenter exploratory trial (NCT07937124, registered November 13, 2026) is evaluating ivosidenib, sonrotoclax (BCL-2 inhibitor), and chidamide (HDAC inhibitor) in combination for newly diagnosed acute myeloid leukemia harboring IDH1 R132 mutation in approximately 30 adult participants.
SALANERSEN (BIIB115) FOR SPINAL MUSCULAR ATROPHY — AGES 15-60
- A Biogen-sponsored study (NCT07444476) is evaluating salanersen (BIIB115), a novel SMA therapy, in participants aged 15 to 60 years, including those treatment-naive and those previously treated with risdiplam, targeting SMN-modifying mechanisms in adult and adolescent SMA.
BLINATUMOMAB IN OLDER ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS
- Phase II trial NCT02143414 continues evaluating blinatumomab, a CD19/CD3 bispecific monoclonal antibody, plus combination chemotherapy or dasatinib-prednisone regimens specifically in older ALL patients, with an update posted November 13, 2026.
RITUXIMAB PLUS IBRUTINIB IN OLDER UNTREATED CLL — PHASE III
- Phase III trial NCT01886872 (updated November 13, 2026) is comparing rituximab with bendamustine or ibrutinib versus ibrutinib alone in older patients with previously untreated chronic lymphocytic leukemia.
CHATBOT FOR INFLUENZA VACCINATION IN ADULTS 65-PLUS
- A randomized controlled trial (NCT07934888, registered November 13, 2026) is testing a rule-based chatbot combined with ChatGPT-supported real-time question-answering to promote seasonal influenza vaccination among community-dwelling adults aged 65 and older.
MODIFIED FRAILTY INDEX FOR HIP FRACTURE OUTCOMES IN OLDER ADULTS
- Prospective observational trial NCT07936279 (registered November 13, 2026) is evaluating the mFI-5 frailty score for predicting ICU need and 30-day mortality after hip fracture surgery in patients aged 65 and older.
📢 PUBLIC HEALTH
DRUG-RESISTANT BACTERIA SURGE
- A CDC report released September 23, 2026, found a dramatic increase in dangerous drug-resistant bacteria in the United States, reinforcing antimicrobial resistance as a parallel threat to infectious disease control.
ONGOING LISTERIA OUTBREAK LINKED TO PREPARED MEALS
- As of October 30, 2026, CDC is urging consumers to check refrigerators and freezers for recalled prepared meal products as illnesses continue despite prior recalls; the outbreak has included multiple deaths and was expanded in September to include additional prepared foods.
SALMONELLA IN MORINGA LEAF PRODUCTS — EXTENSIVELY DRUG-RESISTANT STRAIN
- An extensively drug-resistant Salmonella outbreak linked to moringa powder capsules, with three hospitalizations, was flagged by CDC in February 2026 and updated through May 2026 with a growing number of illnesses across 28 states and multiple product recalls.
RABIES ACTIVITY INCREASING
- CDC issued a statement on September 10, 2026, flagging increases in animal rabies activity and associated human exposures across the United States, urging post-exposure prophylaxis awareness.
TICK BITES ABOVE SEASONAL NORM
- CDC data released April 23, 2026, showed weekly emergency room visits for tick bites were higher than usual for that point in the season, underscoring the need for tick bite prevention during outdoor activities.
This briefing is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personal health decisions.
BIOMED PULSE — End of Edition, November 16, 2026
📎 Sources
- Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- CDC Mobilizes International Response Following Ebola Disease O… — CDC Newsroom
- Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20261116-02-v138 · 2026-11-16 02:01 UTC · pulse.uzylab.com